Loading...
01/11 11:26
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary presents a mixed outlook: strong growth in point-of-care revenues and improved financial health, but challenges like restructuring costs, competitive pressures, and lack of shareholder returns. The Q&A section suggests some uncertainties, particularly with the CGM trials and new Premier instruments. Despite positive elements, such as potential growth in clinical chemistry and a new distribution partner, the absence of clear guidance and shareholder return plans tempers optimism, resulting in a neutral sentiment.
Revenue $15.8 million, 14% increase year-over-year. Driven by a 119% increase in point-of-care revenues, primarily from TrinScreen HIV, which had sales of approximately $3.1 million.
Point-of-Care Revenue $4.6 million, 119% increase year-over-year. This increase was driven by the successful scaling of rapid HIV test output.
Clinical Laboratory Revenue $11.3 million, 4.6% decrease year-over-year. Strong performance in clinical chemistry portfolio (+20% year-over-year) was offset by a 10.8% decline in hemoglobins revenue due to lower instrument sales.
Gross Profit $5.7 million, gross margin of 36.2%, consistent with Q2 2023. Improved gross margins in hemoglobins offset by dilution from TrinScreen HIV sales.
Research and Development Expenses $1 million, down $200,000 year-over-year. Continued development of CGM offering post-acquisition.
SG&A Expenses $6.4 million, down $1.5 million year-over-year. Reduction primarily due to lower employee remuneration costs from headcount optimization.
Restructuring Costs $1.9 million incurred related to the comprehensive transformation plan, mainly for termination payments and factory closure costs.
Noncash Impairment Charge $0.4 million, compared to $10.8 million in Q2 2023. Reflects improved valuation of cash-generating units.
Operating Loss $4.1 million, improved from $14.9 million in Q2 2023.
Net Financial Expense $2.8 million, down from $3.8 million in Q2 2023. Decrease mainly due to the absence of a penalty for early loan settlement incurred in Q2 2023.
Net Loss from Continuing Operations $6.8 million, improved from $18.3 million in Q2 2023.
Adjusted EBITDASO $1.4 million, compared to $2.6 million in Q2 2023.
Basic Loss per ADS $0.71, compared to $0.78 in Q2 2023.
Cash Balance $5.3 million at the end of June, down from $5.8 million at March 31. Cash used by operations improved by $3.3 million year-over-year.
Investing Cash Outflows $3.2 million, mainly related to R&D capital expenditure for CGM and hemoglobin products.
Cash Inflow from Financing Activities $3.9 million, primarily from a $6.5 million drawdown from lenders.
TrinScreen HIV revenue growth: Over 50% quarter-on-quarter revenue growth in point of care revenue, driven by the continued successful scaling of rapid HIV test output.
Continuous Glucose Monitoring (CGM) technology: Development of next-generation CGM device with a focus on affordability, sustainability, and user experience.
Market interest in TrinScreen HIV: Significant interest from key stakeholders at the International AIDS conference for sourcing high-quality tests.
CGM market potential: Opportunity to disrupt the diabetes care market with a more affordable and sustainable CGM solution.
Operational efficiency improvements: Implemented further automation in manufacturing processes, reducing net manufacturing costs.
Offshoring manufacturing: Successfully completed technical transfer of rapid HIV product manufacturing to an offshore partner.
Comprehensive transformation plan: Focus on consolidating and offshoring manufacturing, optimizing supply chain, and centralizing corporate services.
Regulatory Issues: The company is preparing data to support upcoming submissions to relevant regulators for commercial manufacturing with an outsourced partner, with expectations for approval later this year.
Supply Chain Challenges: The company is transitioning a significant portion of its hemoglobin instrumentation supply chain to lower-cost providers, which is expected to be gross margin accretive but may pose risks during the transition.
Economic Factors: The company is experiencing a decline in instrument sales, which is attributed to repositioning its instrument offering in line with a new diabetes column system.
Competitive Pressures: The company faces competition in the continuous glucose monitoring market, particularly from established players like Abbott and Dexcom, necessitating a focus on affordability and sustainability to differentiate its product.
Restructuring Costs: The company incurred restructuring costs totaling $1.9 million related to its comprehensive transformation plan, which may impact short-term financial performance.
Impairment Charges: The company recorded a noncash impairment charge of $0.4 million, indicating potential risks related to the valuation of its cash-generating units.
Transformation Plan: The comprehensive transformation plan aims to deliver a lower manufacturing and SG&A cost base, driving significant profitability from growing revenues. It has three main pillars: consolidate and offshore manufacturing, optimize supply chain, and centralize offshore corporate services.
TrinScreen HIV Revenue Growth: The company reported over 50% quarter-on-quarter revenue growth in point of care revenue, driven by the successful scaling of rapid HIV test output, with a year-over-year increase of almost 120%.
Continuous Glucose Monitoring (CGM) Development: Trinity Biotech is focused on building a global business in wearable biosensors, particularly CGM technology, with a unique reusable sensor applicator that reduces costs and waste.
Revenue Guidance: The company is on track to achieve annualized run rate revenues of approximately $75 million by Q2 2025.
EBITDASO Guidance: Expected EBITDASO of approximately $20 million by Q2 2025.
Capital Expenditure: Overall capital expenditure for Q2 2024 related to the CGM division was $2.8 million.
Share Buyback Program: None
Dividend Program: None
The earnings call reveals mixed signals. Financial performance shows improvement in losses and revenue growth in key areas, but there are ongoing financial challenges, competitive pressures in the CGM market, and operational risks due to restructuring. The lack of a clear shareholder return plan and unclear management responses in the Q&A add uncertainty. Despite positive revenue growth in TrinScreen HIV and cost reduction efforts, the net loss and financial risks limit optimism, resulting in a neutral stock price prediction.
The earnings call summary presents a mixed outlook: strong growth in point-of-care revenues and improved financial health, but challenges like restructuring costs, competitive pressures, and lack of shareholder returns. The Q&A section suggests some uncertainties, particularly with the CGM trials and new Premier instruments. Despite positive elements, such as potential growth in clinical chemistry and a new distribution partner, the absence of clear guidance and shareholder return plans tempers optimism, resulting in a neutral sentiment.
The earnings call presents a mixed picture. While there are improvements in operating and net losses, and revenue growth in the Point-of-Care business, the company faces challenges such as declining clinical laboratory revenues and high debt levels. The Q&A reveals management's reluctance to provide specific details, which may concern investors. Overall, the financial performance and business updates are balanced, leading to a neutral sentiment.
The earnings call highlights strong financial management, with reduced financial expenses and a gain from discontinued operations. The Q&A session reveals positive developments like the approval of new diabetes products and plans for market expansion in Africa. While there are some uncertainties, such as the timeline for CGM revenue, the overall sentiment is optimistic with expected revenue growth, cost-saving initiatives, and strategic market positioning. These factors suggest a positive stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
